Gyre Therapeutics (GYRE) Net Income towards Common Stockholders Growth (5y) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Gyre Therapeutics | 532.38 Mn | 518.25 Mn | 8.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 17.28% |
| Dec 31, 2025 | 38.07% |
| Sep 30, 2025 | 17.35% |
| Jun 30, 2025 | 15.16% |
| Mar 31, 2025 | 21.66% |
| Dec 31, 2024 | 62.64% |
| Sep 30, 2024 | 15.87% |
| Jun 30, 2024 | 17.67% |
| Mar 31, 2024 | 20.11% |
| Dec 31, 2023 | -56.27% |
| Sep 30, 2023 | 20.27% |
| Jun 30, 2023 | 17.98% |
| Mar 31, 2023 | 19.58% |
| Dec 31, 2022 | -39.05% |
| Sep 30, 2022 | 3.36% |
| Jun 30, 2022 | 48.63% |
| Mar 31, 2022 | -28.57% |
| Dec 31, 2021 | -40.19% |
| Sep 30, 2021 | -39.54% |
| Jun 30, 2021 | -32.75% |
| Mar 31, 2021 | -44.25% |
| Dec 31, 2020 | -23.78% |
| Sep 30, 2020 | -34.73% |
| Jun 30, 2020 | -31.80% |
| Mar 31, 2020 | 9.70% |
| Dec 31, 2019 | -24.47% |
| Sep 30, 2019 | -21.19% |
| Jun 30, 2019 | -11.11% |
| Mar 31, 2019 | -0.11% |
| Dec 31, 2018 | 4.10% |
| Sep 30, 2018 | 9.82% |
| Jun 30, 2018 | 12.13% |
| Mar 31, 2018 | 8.97% |
| Dec 31, 2017 | 18.53% |
| Sep 30, 2017 | 5.97% |
| Jun 30, 2017 | -21.78% |
| Mar 31, 2017 | -30.82% |
| Dec 31, 2016 | 17.49% |
| Sep 30, 2016 | 12.03% |
| Jun 30, 2016 | -16.45% |
| Mar 31, 2016 | -17.98% |
| Dec 31, 2015 | -24.63% |
| Sep 30, 2015 | -28.13% |
| Jun 30, 2015 | -25.77% |